Abstract

Zimmer Biomet is scheduled to report quarterly results on August 05, 2026, Pre-Market; this preview synthesizes the latest quarterly actuals, the current-quarter forecasts, and recent institutional commentary to frame expectations for revenue, profitability, and EPS.

Market Forecast

Market expectations point to a modest acceleration in top line and stable earnings for the upcoming quarter: revenue is estimated at 2.13 billion US dollars, implying 3.97% year-over-year growth; adjusted EPS is projected at 2.01, up 1.29% year over year; and EBIT is forecast at 553.05 million US dollars, down 1.78% year over year. Forecasts for gross profit margin and net profit margin are not available in the collected estimates; if management provides margin commentary on the call, investors will recalibrate expectations accordingly.

Within the company’s business mix, reconstructive knees and hips remain the core revenue drivers, with last quarter knee revenue at 828.60 million US dollars and hip revenue at 524.10 million US dollars, positioning the franchise for steady procedure-driven demand and stable mix into the print. The most promising adjacent growth platform is the “Surgical, Sports Medicine, Biologics, Foot and Ankle, Extremities and Trauma” category, which delivered 562.20 million US dollars last quarter; year-over-year change for that segment is not disclosed in the available data, but catalysts include continued uptake of digital and robotics solutions and accretive contributions from the iovera° cryoanalgesia asset integration.

Last Quarter Review

Zimmer Biomet delivered a solid prior quarter, posting revenue of 2.09 billion US dollars, up 9.30% year over year, with a gross profit margin of 72.96%, GAAP net profit attributable to shareholders of 238.00 million US dollars, a net profit margin of 11.41%, and adjusted EPS of 2.09, up 15.47% year over year; net profit also improved sequentially with a quarter-on-quarter change of 70.93%.

A notable financial highlight was profitability outperformance versus the market’s prior expectations: EBIT came in at 570.50 million US dollars, exceeding consensus by 47.86 million US dollars, and adjusted EPS of 2.09 surpassed estimates by 0.23, indicating healthy operating leverage on the better-than-expected top line. In terms of the business mix, knees generated 828.60 million US dollars (approximately 39.71% of the quarter’s revenue), hips produced 524.10 million US dollars (about 25.12%), the “Surgical, Sports Medicine, Biologics, Foot and Ankle, Extremities and Trauma” category contributed 562.20 million US dollars (roughly 26.94%), and other businesses added 171.80 million US dollars; segment-level year-over-year growth rates were not disclosed in the available dataset, though the 9.30% year-over-year expansion at the consolidated level implies broad-based momentum.

Current Quarter Outlook

Main business trajectory

The upcoming quarter’s results are likely to reflect stable procedural volumes and resilient utilization across reconstructive knees and hips, consistent with the revenue estimate of 2.13 billion US dollars and a 3.97% year-over-year growth pace implied by current forecasts. The model anticipates only slight year-over-year EPS expansion at 1.29%, which suggests that pricing and mix tailwinds in core reconstructive should be balanced by normalization in operating expenses and selective investment in commercial and R&D priorities. Given the prior-quarter gross margin at 72.96%, investors will pay close attention to product mix and manufacturing absorption trends to gauge the sustainability of margins as implant volumes remain consistent and capital equipment/order seasonality is absorbed.

A central debate for the quarter is how knee and hip mix evolves as premium technologies gain share within the installed base. Premium implants and enabling technologies tend to carry higher gross margins but may also be accompanied by incremental investment in surgical support and service. If the mix tilts favorably, gross margin could hold near the prior run-rate even without explicit guidance; if mix skews to more value-focused constructs, margin could compress slightly, pressuring the EPS bridge despite revenue growth. The EBIT forecast of 553.05 million US dollars and its year-over-year decline of 1.78% signal the market’s expectation of moderate operating-spend growth and potential absorption of cost items in the quarter, a setup that still allows for modest EPS gains thanks to revenue scale and lower interest expense tailwinds.

Expectations for knee and hip volume stability also hinge on hospital throughput and staffing, two dynamics that influenced prior periods. Utilization remains the essential swing factor for reconstructive throughput, so commentary on procedure backlogs, scheduling efficiency, and case mix will likely guide how investors frame the second half. With adjusted EPS expected at 2.01, the market appears to have discounted limited upside in operating leverage this quarter, placing greater weight on the durability of demand and the visibility of the top-line run-rate heading into the back half of the year.

Most promising business and catalysts

The “Surgical, Sports Medicine, Biologics, Foot and Ankle, Extremities and Trauma” portfolio provides the most visible catalyst stack in the near term, given its adjacency to core reconstruction and its sensitivity to product-cycle innovation. Last quarter’s 562.20 million US dollars from this category underscores the scale of this profit contributor, which benefits from continued portfolio enhancements and integration opportunities. The recently announced agreement to acquire the iovera° cryoanalgesia system from Pacira adds a complementary perioperative pain-management solution that can be coordinated across sports medicine, extremities, and reconstructive pathways, potentially improving the overall procedural value proposition.

Digital surgery and robotics remain strategic accelerators within this mix, primarily through pull-through of implant and instrument revenue rather than standalone hardware recognition. As installed bases expand and utilization per system increases, the expected monetization grows via higher case counts, premium implant attachment, and service contracts. Because this economic model monetizes over the life of each system, incremental momentum may appear in gradual revenue accretion rather than sudden spikes, yet it typically supports better gross margins owing to the value proposition of enabling technology. Management commentary on placements, utilization, and pipeline conversions will be important context for evaluating how the surgical and sports medicine categories contribute to margin resilience through the year.

From a portfolio standpoint, the adjacency strategy knits together pre- and post-operative care elements, joint preservation options, and surgical instrumentation that collectively enhance the revenue synergy around each procedure. The integration of iovera° dovetails with this approach by expanding the perioperative toolkit. As this platform scales, the effect on consolidated margins could be favorable if premium product mix and service intensity outpace commodity-like components. Although year-over-year segment growth data are not available in the collected dataset, the contribution profile and the cadence of innovation suggest this category can continue to deliver incremental growth and help stabilize consolidated profitability in the medium term.

Key stock-price swing factors this quarter

Margin and mix will likely be the primary drivers for the share price reaction on the print. With last quarter’s gross profit margin at 72.96% and net profit margin at 11.41%, the market will parse whether similar levels are sustainable as product mix evolves. Any upside surprise on gross margin or evidence of expense control that protects EBIT—relative to the 553.05 million US dollars market estimate—would likely translate to EPS upside, given the narrow 1.29% year-over-year EPS expansion currently embedded in expectations. Conversely, if implant mix skews lower than anticipated or if inflationary inputs and logistics create incremental pressure, EBIT could undershoot, and shares may reflect the shortfall given limited implied buffer.

Capital allocation is an additional swing factor to watch over the next few quarters. The company has indicated it expects to repurchase up to 1.00 billion US dollars of stock in fiscal 2026 under an existing authorization, which provides a supportive framework for per-share earnings metrics and offers flexibility to absorb small variances in quarterly performance. Recently executed revolving credit agreements, including a five-year facility and a 364-day facility, enhance liquidity management and provide optionality for working capital, M&A, and opportunistic buybacks. Clarity on the cadence of buyback execution and leverage targets may influence how investors model second-half EPS and free cash flow yields.

Strategic updates remain a meaningful catalyst for sentiment. The integration of the iovera° asset is likely to receive investor attention for its potential revenue and margin implications in sports medicine and perioperative care. Commentary around the commercial momentum of digital and robotics platforms—particularly utilization and attachment rates—will further shape how the market values the medium-term margin profile. Finally, external opinions can sway near-term trading: an upgrade to Buy with a price target of 115 US dollars by a major global investment bank shortly before the print underscored improving confidence in execution, while a Sell rating from another large firm earlier in the period highlights the divergence in views on valuation and near-term operating leverage. Management’s tone on guidance and second-half visibility may therefore be a crucial determinant of the stock’s immediate reaction.

Analyst Opinions

Across recent months, the balance of explicit Buy versus Sell opinions skews bullish by a 3:1 margin. On the bullish side, a prominent global bank upgraded Zimmer Biomet to Buy with a 115 US dollars price target, citing better confidence in execution ahead of the upcoming report and improved visibility on catalysts. Another international investment firm maintained a Buy stance earlier in the period, emphasizing the company’s potential for operational improvements and the benefits of portfolio initiatives. A U.S.-based research house also reaffirmed its Buy rating with a 112 US dollars price target in February, reflecting expectations for continued earnings stability and incremental upside from capital allocation and product cycles.

This bullish cohort centers its case on several pillars. First, the quarter’s revenue estimate of 2.13 billion US dollars with 3.97% year-over-year growth presents a manageable hurdle relative to the prior quarter’s 2.09 billion US dollars and 9.30% year-over-year gain, indicating that consistent execution rather than dramatic acceleration is required to meet expectations. Second, the EPS estimate of 2.01 up 1.29% year over year implies only a small improvement, which could be exceeded if gross margin mix holds near the prior 72.96% level and if operating expenses remain disciplined. Third, catalysts embedded in the adjacency portfolio—including the integration of iovera° and ongoing digital/robotics adoption—offer incremental revenue and profitability tailwinds over the medium term, supporting a favorable risk-reward profile even if near-term EBIT growth is modest.

These analysts also point to capital allocation as an underpinning for per-share metrics and share-price support. The up to 1.00 billion US dollars repurchase target for fiscal 2026 provides a clear framework for offsetting dilution and supporting EPS growth, especially in quarters where operating leverage is limited. The availability of new revolving credit capacity adds flexibility to manage working capital and strategic investments without undue strain on the balance sheet. When combined with evidence of prior-quarter execution—EBIT of 570.50 million US dollars outperforming consensus by 47.86 million US dollars and adjusted EPS beating by 0.23—the bullish view argues that the setup into the print is balanced to slightly positive.

While divergent opinions exist elsewhere in the analyst community, the bullish perspective currently holds the numerical advantage over explicit Sell ratings in the recent period reviewed. In their view, execution on core reconstructive volumes, steady gross margins, and measured expense management are sufficient to meet or modestly exceed the conservative EPS growth implied by the consensus. Any incremental positive signal on digital adoption, adjacency monetization, or capital return cadence would reinforce this stance and could widen the gap between Buy and Sell narratives post-print.